LOGO
LOGO

quick facts

  • Target Shareholders Reject Independent Chair Policy Proposal June 13, 2026 10:50 ET

    Target Corp. (TGT) announced the results of its 2026 Annual Meeting of Shareholders held on June 10, 2026. Shareholders rejected three proposals, including a request for a policy requiring the Board Chair to be independent, a report on the presence of pesticides in Target's private label brands, and...

  • JBS USA To Close Facilities In Pennsylvania And Tennessee, Pledges Support For Employees June 13, 2026 04:37 ET

    JBS USA announced plans to close two facilities located in Pennsylvania and Tennessee as part of targeted changes aimed at strengthening its operations for the future. The company emphasized its commitment to supporting employees impacted by the decision. The closures include the beef production facility...

  • Roche Secures FDA Approval For First PTEN IHC Companion Diagnostic In Prostate Cancer June 13, 2026 03:19 ET

    Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug Administration (FDA) for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with...

  • OpenText Doubles Ireland Investment With EUR 105 Mln Commitment And 400 New Jobs June 13, 2026 03:05 ET

    OpenText (OTEX, OTEX.TO) has announced a 105 million euros investment that will create 400 new jobs across its sites in Ireland over the next three years. This commitment doubles the company's investment in the country and will significantly expand its capabilities in agentic AI, cybersecurity, sovereign...

  • AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer June 13, 2026 02:43 ET

    AstraZeneca's (AZN,AZN.L,ZEG.DE,AZN.ST) Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer—previously...

  • FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes June 13, 2026 02:01 ET

    Sanofi (SNY) announced that the U.S. Food and Drug Administration has granted accelerated approval to Tzield (teplizumab-mzwv) for delaying the decline in endogenous insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield is not effective as a disease-modifying...

  • SpaceX Commences Trading On Nasdaq After Record $75 Billion IPO June 12, 2026 11:04 ET

    Much-awaited shares of Space Exploration Technologies Corp. (SPCX) have finally begun trading on the Nasdaq at $135 per share following the company's initial public offering (IPO) of 555.56 million Class A common shares, priced at $135 each. However, a recent Wall Street Journal report suggests that...

  • ING Cuts TMBThanachart Bank Stake To 19.5% In EUR 243 Mln Buyback June 12, 2026 09:27 ET

    Dutch bank ING Groep N.V.(ING, INGA.AS, INN1.DE, 1INGA.MI) announced on Friday that it has cut its stake in Thailand's TMBThanachart Bank or TTB to 19.5 percent from 23.1 percent by participating in the lender's share buyback program. The company received gross proceeds of about 243 million euros...

  • Jazz Pharmaceuticals Phase 3 LAGOON Trial Fails To Meet Primary Endpoint Of Overall Survival June 12, 2026 09:14 ET

    Friday, Jazz Pharmaceuticals plc (JAZZ) announced that the Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in patients with relapsed metastatic small cell lung cancer, did not meet its primary endpoint of overall survival. The trial, conducted by , comprised of three arms: one arm to receive...

  • 51Talk Online Education Posts Wider Loss In Q1 June 12, 2026 07:37 ET

    51Talk Online Education Group (COE) reported a first quarter net loss attributable to ordinary shareholders of $2.3 million, compared with a net loss of $1.7 million, a year ago. Net loss per share was $0.01, compared with a loss of $0.005. Net loss per ADS was $0.39, compared with a loss of $0.29. Excluding...

  • Expensify Buybacks 6.05 Mln Shares At $1.20/shr In Tender Offer June 12, 2026 07:32 ET

    Expensify, Inc. (EXFY), an expense management software company, on Friday announced the final results of its modified Dutch auction tender offer to purchase up to $25 million of its Class A common stock. The company accepted 6,053,023 shares for purchase at $1.20 per share for approximately $7.3 million....

  • Medallion Bank Names Justin Haley CEO To Succeed Donald Poulton June 12, 2026 07:23 ET

    FDIC-insured lender Medallion Bank (MBNKO) announced on Friday that it named President Justin Haley as Chief Executive Officer, effective July 1, succeeding Donald Poulton, who will retire on June 30. The Bank said Poulton will join the bank's board as Chair of the risk committee. Haley was promoted...

  • AES Prices $1 Bln Public Offering Of Senior Notes June 12, 2026 07:22 ET

    The AES Corp. (AES), an energy company, on Thursday announced the pricing of a public offering of $1 billion aggregate principal amount of senior notes. The offering is expected to close on June 16. The offering consists of $600 million of 5.200% senior notes due 2029 and $400 million of 5.750%...

  • Invitation Homes Declares Q3 Dividend Of $0.30/Shr June 12, 2026 07:15 ET

    Invitation Homes Inc. (INVH), a single-family home leasing and management company, on Friday announced that its board of directors declared a quarterly cash dividend The dividend is of $0.30 per share for the third quarter of 2026. The dividend will be paid on or before July 17 to shareholders...

  • Simcere Pharma Reveals Research Deal With Stanford Medicine To Develop Treatment For IPF June 12, 2026 04:54 ET

    Simcere Pharmaceutical Group Ltd. (2096.HK) announced on Friday that it has entered into a research collaboration agreement with Stanford Medicine to develop a treatment for irreversible Idiopathic Pulmonary Fibrosis or IPF, a chronic lung disease of unknown origin and with no known cure. Under the...

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.